Hematuria Evaluation

Cxbladder Triage

Cxbladder Triage is a frontline diagnostic. The test is optimized to help de-intensify clinical work-up in hematuria patients with a low probability of urothelial bladder cancer, reducing the need for referral and invasive procedures, while prioritizing those who require further investigation.​

Triage supports a new model for clinical practice and resource utilisation. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.

Cxbladder Detect

Cxbladder Detect is designed to improve practice workflow and efficiency in secondary urological care while giving patients the best experience possible. The test is optimized for the risk stratification of patients presenting with hematuria and helps to de-intensify clinical work-up in in those with a low probability of urothelial bladder cancer.

In cases of diagnostic ambiguity - atypical cytology and equivocal cystoscopy - Cxbladder Detect helps to resolve uncertainty, reducing the likelihood of a missed tumor.

Cxbladder Detect*

Designed as a single diagnostic for hematuria evaluation, Cxbladder Detect+ is a next generation Cxbladder test that combines an analysis of 5 core mRNA biomarkers with DNA markers to deliver significant performance improvements over our existing tests. 

The commercial launch of Cxbladder Detect+ is expected soon.

Bladder Cancer Surveillance

Cxbladder Monitor

Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients being monitored for recurrent non-muscle bladder cancer. In suitable cases Monitor can alternate with cystoscopy to de-intensify surveillance. The test can replace cystoscopy in patients with no recurrence long term after shared decision between doctor and patient.

With the option of in-home sampling, Monitor improves patient comfort and compliance with cancer surveillance and management regimes.